FDMT
Conviction 94HealthcareScan · Thu, Sep 24, 20264D Molecular Therapeutics, Inc. (FDMT) closed at $14.72 (-1.87%) on Sep 24, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 54, RS Rating 94, -12.2% from its 52-week high, +101.1% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).
Financials as of Tue, Jun 30, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in FDMT
Insider activity
SEC Form 4 transactions in FDMT · open-market 4 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Kirn David See Remarks · Stock Option (Right to Buy) · 2026-08-19 | Exercise | 50K | — | 2026-08-19 | 2026-08-21 |
Kirn David See Remarks · Common Stock · 2026-08-19 | Sell | 25.93K | $426K | 2026-08-19 | 2026-08-21 |
Kirn David See Remarks · Common Stock · 2026-08-19 | Sell | 43.15K | $663K | 2026-08-19 | 2026-08-21 |
Kirn David See Remarks · Common Stock · 2026-08-19 | Exercise | 50K | $207K | 2026-08-19 | 2026-08-21 |
Bizily Scott Chief Legal Officer · Common Stock · 2026-08-17 | Exercise | 1.64K | $7K | 2026-08-17 | 2026-08-17 |
Bizily Scott Chief Legal Officer · Stock Option (Right to Buy) · 2026-08-17 | Exercise | 1.64K | — | 2026-08-17 | 2026-08-17 |
Bizily Scott Chief Legal Officer · Common Stock · 2026-08-17 | Sell | 1.64K | $20K | 2026-08-17 | 2026-08-17 |
Bizily Scott Chief Legal Officer · Common Stock · 2026-08-13 | Sell | 1.64K | $20K | 2026-08-13 | 2026-08-17 |
Bizily Scott Chief Legal Officer · Common Stock · 2026-08-13 | Exercise | 1.64K | $7K | 2026-08-13 | 2026-08-17 |
Bizily Scott Chief Legal Officer · Stock Option (Right to Buy) · 2026-08-13 | Exercise | 1.64K | — | 2026-08-13 | 2026-08-17 |
SEC filings
EDGAR filings in FDMT · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.